CN102181520A - 甲基化slc19a3基因的应用 - Google Patents
甲基化slc19a3基因的应用 Download PDFInfo
- Publication number
- CN102181520A CN102181520A CN 201110048270 CN201110048270A CN102181520A CN 102181520 A CN102181520 A CN 102181520A CN 201110048270 CN201110048270 CN 201110048270 CN 201110048270 A CN201110048270 A CN 201110048270A CN 102181520 A CN102181520 A CN 102181520A
- Authority
- CN
- China
- Prior art keywords
- slc19a3
- gene
- tumour
- application
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091006779 SLC19A3 Proteins 0.000 title claims abstract description 22
- 102100030103 Thiamine transporter 2 Human genes 0.000 title abstract description 22
- 108090000623 proteins and genes Proteins 0.000 title abstract description 14
- 102000037054 SLC-Transporter Human genes 0.000 title abstract 2
- 108091006207 SLC-Transporter Proteins 0.000 title abstract 2
- 101150007894 Slc19a3 gene Proteins 0.000 claims abstract description 83
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 39
- 238000001514 detection method Methods 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 23
- 230000007067 DNA methylation Effects 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 14
- 238000011144 upstream manufacturing Methods 0.000 claims description 13
- 238000011529 RT qPCR Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 201000000498 stomach carcinoma Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000011987 methylation Effects 0.000 abstract description 24
- 238000007069 methylation reaction Methods 0.000 abstract description 24
- 210000004881 tumor cell Anatomy 0.000 abstract description 18
- 210000005259 peripheral blood Anatomy 0.000 abstract description 14
- 239000011886 peripheral blood Substances 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 12
- 238000003745 diagnosis Methods 0.000 abstract description 11
- 238000012216 screening Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 41
- 238000006243 chemical reaction Methods 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 12
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 206010017758 gastric cancer Diseases 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 230000006607 hypermethylation Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 230000017858 demethylation Effects 0.000 description 5
- 238000010520 demethylation reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000001035 methylating effect Effects 0.000 description 4
- HMHNEALJNYAPJE-UHFFFAOYSA-N oxalonitrile sulfurous acid Chemical compound N#CC#N.S(=O)(O)O HMHNEALJNYAPJE-UHFFFAOYSA-N 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009514 concussion Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007855 methylation-specific PCR Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 101100519160 Arabidopsis thaliana PCR4 gene Proteins 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000727774 Homo sapiens Thiamine transporter 2 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100331535 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DIB1 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- -1 Sulfurous acid cyanogen salt Chemical class 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-N dithionous acid Chemical compound OS(=O)S(O)=O GRWZHXKQBITJKP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110048270 CN102181520B (zh) | 2011-03-01 | 2011-03-01 | 甲基化slc19a3基因的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110048270 CN102181520B (zh) | 2011-03-01 | 2011-03-01 | 甲基化slc19a3基因的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102181520A true CN102181520A (zh) | 2011-09-14 |
CN102181520B CN102181520B (zh) | 2013-02-06 |
Family
ID=44567806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110048270 Expired - Fee Related CN102181520B (zh) | 2011-03-01 | 2011-03-01 | 甲基化slc19a3基因的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102181520B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333962A (zh) * | 2013-06-21 | 2013-10-02 | 黑龙江省医学科学院 | 一种用于人乳腺癌特异性甲基化检测的引物、探针及其应用 |
CN107400704A (zh) * | 2016-05-20 | 2017-11-28 | 博尔诚(北京)科技有限公司 | 一种用于乳腺癌筛查的组合物及其应用 |
CN107988366A (zh) * | 2017-12-22 | 2018-05-04 | 深圳市宝安区妇幼保健院 | 一种用于诊断评估乳腺癌的试剂盒、甲基化hoxa4/dpp6基因的检测及其应用 |
-
2011
- 2011-03-01 CN CN 201110048270 patent/CN102181520B/zh not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
《Biochimica et Biophysica Acta》 20011231 Arun Rajgopal等 SLC19A3 encodes a second thiamine transporter ThTr2 175-178 1-7 第1537卷, 第3期 * |
《Cancer Research》 20101215 EKO Ng等 Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients 1 1-7 第70卷, 第24(增刊2)期 * |
《Tumor biology》 20091231 Xin Liu等 Promoter hypermethylation mediates downregulation of thiamine receptor SLC19A3 in gastric cancer 242-248 6-7 第30卷, 第5-6期 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103333962A (zh) * | 2013-06-21 | 2013-10-02 | 黑龙江省医学科学院 | 一种用于人乳腺癌特异性甲基化检测的引物、探针及其应用 |
CN107400704A (zh) * | 2016-05-20 | 2017-11-28 | 博尔诚(北京)科技有限公司 | 一种用于乳腺癌筛查的组合物及其应用 |
CN107988366A (zh) * | 2017-12-22 | 2018-05-04 | 深圳市宝安区妇幼保健院 | 一种用于诊断评估乳腺癌的试剂盒、甲基化hoxa4/dpp6基因的检测及其应用 |
CN107988366B (zh) * | 2017-12-22 | 2020-07-14 | 深圳市宝安区妇幼保健院 | 一种用于诊断评估乳腺癌的试剂盒、甲基化hoxa4/dpp6基因的检测及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102181520B (zh) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shaker et al. | Role of microRNAs-29b-2,− 155,− 197 and− 205 as diagnostic biomarkers in serum of breast cancer females | |
CN104946739B (zh) | Egfr基因突变检测试剂盒及其应用 | |
CN105624274B (zh) | 肿瘤靶向药物相关基因突变高通量检测方法、引物及试剂 | |
CN106148498B (zh) | Kras基因突变检测试剂盒及其应用 | |
Sugita et al. | Quantitative molecular diagnosis of peritoneal lavage fluid for prediction of peritoneal recurrence in gastric cancer | |
CN102936597A (zh) | 一种用于结直肠癌大量筛查的生物标记物 | |
CN102181520B (zh) | 甲基化slc19a3基因的应用 | |
CN106191055A (zh) | 一种非小细胞肺癌标志物、检测试剂及试剂盒 | |
CN109371022A (zh) | 一种环状RNA hsa_circKPNA2_002及其特异性扩增引物和应用 | |
CN111893188A (zh) | 生物标志物linc01356在宫颈癌诊断和治疗中的应用 | |
CN104774966B (zh) | 肺腺癌miRNA标记物 | |
CN106939354B (zh) | miRNA-4530作为肺癌诊断标志物的应用 | |
CN107893115B (zh) | Alkbh1基因及其表达产物在制备用于诊断肿瘤的试剂盒、治疗肿瘤的药物中的用途 | |
CN109055552A (zh) | 检测Septin9基因启动子是否甲基化的方法及其专用成套试剂 | |
JP6143920B1 (ja) | 卵巣がんの予後診断マーカーとしてのmmp1遺伝子転写産物と検査法 | |
CN103361404A (zh) | 一种检测肝癌相关风险基因的试剂盒 | |
CN103255210A (zh) | Line-1基因甲基化定量检测方法 | |
CN106929599B (zh) | miRNA-6126作为肺癌诊断标志物的应用 | |
CN103695556A (zh) | 口腔癌诊断、预防或治疗中应用的试剂盒及药物 | |
CN110699450A (zh) | miRNA生物标志物在肝脏疾病诊断和预后判断中的应用 | |
CN102443634A (zh) | Fbp1基因的应用 | |
CN113373151B (zh) | 环状RNAhsa_circ_0008399的应用 | |
CN102409096A (zh) | 甲基化fbp1基因的应用 | |
CN108118093A (zh) | Linc00426在制备骨肉瘤转移诊断产品中的用途 | |
Lin et al. | Promoter hypermethylation of p16 gene and DAPK gene in sera from hepatocellular carcinoma (HCC) patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HANGZHOU EACTION BIO-TECH CO., LTD. Free format text: FORMER OWNER: HANGZHOU BOPU MEDICAL TECHNOLOGY CO.,LTD. Effective date: 20140507 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140507 Address after: Hangzhou City, Zhejiang province 311121 Xihu District Ancient Jade Road 98, building 2 Patentee after: HANGZHOU EACTION BIOTECHNOLOGY Co.,Ltd. Address before: Yuhang District, Hangzhou City, Zhejiang Province, 311121 West No. 1500 Building No. 2 Room 308 Patentee before: Hangzhou Bopu Medical Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20221205 Address after: Room 304, 3/F, Building 6, No. 688, Bin'an Road, Changhe Street, Binjiang District, Hangzhou City, Zhejiang Province 310052 Patentee after: Bosu Medical Technology (Hangzhou) Co.,Ltd. Address before: 311121 Building 2, No. 98, Yugu Road, Xihu District, Hangzhou, Zhejiang Patentee before: HANGZHOU EACTION BIOTECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130206 |
|
CF01 | Termination of patent right due to non-payment of annual fee |